These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
30. Characterization of a Broadly Neutralizing Monoclonal Antibody against SARS-CoV-2 Variants. Zakir TS; Meng T; Carmen LCP; Chu JJH; Lin RTP; Prabakaran M Viruses; 2022 Jan; 14(2):. PubMed ID: 35215823 [TBL] [Abstract][Full Text] [Related]
31. Receptor-binding domain-specific human neutralizing monoclonal antibodies against SARS-CoV and SARS-CoV-2. Yu F; Xiang R; Deng X; Wang L; Yu Z; Tian S; Liang R; Li Y; Ying T; Jiang S Signal Transduct Target Ther; 2020 Sep; 5(1):212. PubMed ID: 32963228 [TBL] [Abstract][Full Text] [Related]
32. Novel bispecific human antibody platform specifically targeting a fully open spike conformation potently neutralizes multiple SARS-CoV-2 variants. Kim JW; Heo K; Kim HJ; Yoo Y; Cho HS; Jang HJ; Lee HY; Ko IY; Woo JR; Cho YB; Lee JH; Yang HR; Shin HG; Choi HL; Hwang K; Kim S; Kim H; Chun K; Lee S Antiviral Res; 2023 Apr; 212():105576. PubMed ID: 36870394 [TBL] [Abstract][Full Text] [Related]
33. The SARS-CoV-2 Spike Glycoprotein as a Drug and Vaccine Target: Structural Insights into Its Complexes with ACE2 and Antibodies. Papageorgiou AC; Mohsin I Cells; 2020 Oct; 9(11):. PubMed ID: 33105869 [TBL] [Abstract][Full Text] [Related]
34. V367F Mutation in SARS-CoV-2 Spike RBD Emerging during the Early Transmission Phase Enhances Viral Infectivity through Increased Human ACE2 Receptor Binding Affinity. Ou J; Zhou Z; Dai R; Zhang J; Zhao S; Wu X; Lan W; Ren Y; Cui L; Lan Q; Lu L; Seto D; Chodosh J; Wu J; Zhang G; Zhang Q J Virol; 2021 Jul; 95(16):e0061721. PubMed ID: 34105996 [TBL] [Abstract][Full Text] [Related]
35. Competitive SARS-CoV-2 Serology Reveals Most Antibodies Targeting the Spike Receptor-Binding Domain Compete for ACE2 Binding. Byrnes JR; Zhou XX; Lui I; Elledge SK; Glasgow JE; Lim SA; Loudermilk RP; Chiu CY; Wang TT; Wilson MR; Leung KK; Wells JA mSphere; 2020 Sep; 5(5):. PubMed ID: 32938700 [TBL] [Abstract][Full Text] [Related]
36. The spike-ACE2 binding assay: An in vitro platform for evaluating vaccination efficacy and for screening SARS-CoV-2 inhibitors and neutralizing antibodies. Zhang S; Gao C; Das T; Luo S; Tang H; Yao X; Cho CY; Lv J; Maravillas K; Jones V; Chen X; Huang R J Immunol Methods; 2022 Apr; 503():113244. PubMed ID: 35218866 [TBL] [Abstract][Full Text] [Related]
37. Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection. Hwang YC; Lu RM; Su SC; Chiang PY; Ko SH; Ke FY; Liang KH; Hsieh TY; Wu HC J Biomed Sci; 2022 Jan; 29(1):1. PubMed ID: 34983527 [TBL] [Abstract][Full Text] [Related]
38. Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2. Tai W; Zhang X; He Y; Jiang S; Du L Antiviral Res; 2020 Jul; 179():104820. PubMed ID: 32405117 [TBL] [Abstract][Full Text] [Related]
39. Molecular Basis of Mink ACE2 Binding to SARS-CoV-2 and Its Mink-Derived Variants. Su C; He J; Han P; Bai B; Li D; Cao J; Tian M; Hu Y; Zheng A; Niu S; Chen Q; Rong X; Zhang Y; Li W; Qi J; Zhao X; Yang M; Wang Q; Gao GF J Virol; 2022 Sep; 96(17):e0081422. PubMed ID: 36000849 [TBL] [Abstract][Full Text] [Related]